CN101970497B - 抗‑EpCAM抗体及其用途 - Google Patents

抗‑EpCAM抗体及其用途 Download PDF

Info

Publication number
CN101970497B
CN101970497B CN200880015767.4A CN200880015767A CN101970497B CN 101970497 B CN101970497 B CN 101970497B CN 200880015767 A CN200880015767 A CN 200880015767A CN 101970497 B CN101970497 B CN 101970497B
Authority
CN
China
Prior art keywords
antibody
epcam
seq
fragment
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880015767.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101970497A (zh
Inventor
A·M·安娜斯塔斯
F·派特隆泽里
R·德桑提斯
S·阿尔波提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Pharmaceutical Co
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101970497A publication Critical patent/CN101970497A/zh
Application granted granted Critical
Publication of CN101970497B publication Critical patent/CN101970497B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200880015767.4A 2007-04-04 2008-04-02 抗‑EpCAM抗体及其用途 Expired - Fee Related CN101970497B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105628.7 2007-04-04
EP07105628 2007-04-04
PCT/EP2008/053913 WO2008122551A2 (en) 2007-04-04 2008-04-02 Anti-epcam antibody and uses thereof

Publications (2)

Publication Number Publication Date
CN101970497A CN101970497A (zh) 2011-02-09
CN101970497B true CN101970497B (zh) 2017-05-10

Family

ID=38458122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880015767.4A Expired - Fee Related CN101970497B (zh) 2007-04-04 2008-04-02 抗‑EpCAM抗体及其用途

Country Status (21)

Country Link
US (1) US8318911B2 (enExample)
EP (1) EP2142570B1 (enExample)
JP (1) JP5631733B2 (enExample)
KR (1) KR101683884B1 (enExample)
CN (1) CN101970497B (enExample)
AT (1) ATE512988T1 (enExample)
AU (1) AU2008235566B2 (enExample)
BR (1) BRPI0810096A8 (enExample)
CA (1) CA2682296C (enExample)
CY (1) CY1111819T1 (enExample)
DK (1) DK2142570T3 (enExample)
EA (1) EA023679B1 (enExample)
ES (1) ES2367675T3 (enExample)
HR (1) HRP20110620T1 (enExample)
IL (1) IL201196A0 (enExample)
MX (1) MX2009010444A (enExample)
PL (1) PL2142570T3 (enExample)
PT (1) PT2142570E (enExample)
RS (1) RS52040B (enExample)
SI (1) SI2142570T1 (enExample)
WO (1) WO2008122551A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351919A1 (en) 2003-01-24 2018-07-25 University of Utah Methods of predicting mortality risk by determining telomere length
CN102439171B (zh) 2008-12-22 2017-07-14 犹他大学研究基金会 单色多重定量pcr
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2726870B1 (en) * 2011-06-29 2018-10-03 Academia Sinica The capture, purification and release of biological substance using a surface coating
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9494500B2 (en) 2012-10-29 2016-11-15 Academia Sinica Collection and concentration system for biologic substance of interest and use thereof
CA2912216A1 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
EP3328897A1 (en) * 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
JP2019530431A (ja) 2016-07-26 2019-10-24 テッサ・セラピューティクス・プライベート・リミテッド キメラ抗原受容体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020216210A1 (zh) * 2019-04-22 2020-10-29 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
KR102560876B1 (ko) * 2019-06-11 2023-07-28 바이오아트라, 인코퍼레이티드 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
JP7570653B2 (ja) * 2020-08-19 2024-10-22 ▲蘇▼州易慕峰生物科技有限公司 ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976951A (zh) * 2004-02-13 2007-06-06 米克罗麦特股份公司 抗EpCAM免疫球蛋白

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5578287A (en) 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JP3427871B2 (ja) * 1996-06-24 2003-07-22 戸田工業株式会社 コバルト被着型針状磁性酸化鉄粒子粉末
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976951A (zh) * 2004-02-13 2007-06-06 米克罗麦特股份公司 抗EpCAM免疫球蛋白

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon,stomach,prostate and lung cancers;P Went,et al;《British Journal of Cancer》;20061231;第94卷;第128-135页 *
Mab17-1A and cytokines for the treatment of patients with colorectal carcinoma;Jan-Erik Frodin,et al;《Hybridoma and Hybridomics》;20021231;第21卷(第2期);第99-101页 *
人上皮细胞黏附分子融合蛋白真核表达载体的构建_表达及初步鉴定;王春艳,等;《细胞与分子免疫学杂志》;20041231;第20卷(第6期);第765-768页 *

Also Published As

Publication number Publication date
WO2008122551A9 (en) 2009-02-05
ATE512988T1 (de) 2011-07-15
MX2009010444A (es) 2009-10-20
SI2142570T1 (sl) 2012-01-31
EA200970923A1 (ru) 2010-04-30
KR101683884B1 (ko) 2016-12-07
ES2367675T3 (es) 2011-11-07
HRP20110620T1 (hr) 2011-09-30
PT2142570E (pt) 2011-09-13
PL2142570T3 (pl) 2011-11-30
KR20100016237A (ko) 2010-02-12
CA2682296A1 (en) 2008-10-16
EP2142570A2 (en) 2010-01-13
CA2682296C (en) 2017-02-28
US8318911B2 (en) 2012-11-27
CY1111819T1 (el) 2015-10-07
EP2142570B1 (en) 2011-06-15
CN101970497A (zh) 2011-02-09
EA023679B1 (ru) 2016-06-30
JP2010523096A (ja) 2010-07-15
JP5631733B2 (ja) 2014-11-26
WO2008122551A3 (en) 2008-12-04
US20100092491A1 (en) 2010-04-15
IL201196A0 (en) 2010-05-17
AU2008235566A1 (en) 2008-10-16
DK2142570T3 (da) 2011-10-03
WO2008122551A2 (en) 2008-10-16
RS52040B (sr) 2012-04-30
BRPI0810096A8 (pt) 2017-12-26
AU2008235566B2 (en) 2013-06-06
BRPI0810096A2 (pt) 2014-10-21

Similar Documents

Publication Publication Date Title
CN101970497B (zh) 抗‑EpCAM抗体及其用途
CN111944050B (zh) 一种抗b7-h3抗体及其应用
US11155632B2 (en) Anti-CD47 monoclonal antibody and use thereof
US20190321466A1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
CN116731180A (zh) 抗ror1抗体及其制备和使用方法
US20200255536A1 (en) Target for b-cell disorders
CN101421395A (zh) 显示cd63表面表达的细胞的细胞毒性介导
EP4032908A1 (en) Anti-pd-l1 antibody and pharmaceutical use thereof
US20220089727A1 (en) Anti-CD47 monoclonal antibody and use thereof
CN111100204B (zh) 靶向cd20的抗体、其制备方法和应用
HK1148536B (en) Anti-epcam antibody and uses thereof
HK1148536A (en) Anti-epcam antibody and uses thereof
CN118184785A (zh) Cea抗体及其应用
HK40010330A (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148536

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171204

Address after: Milan Italy

Patentee after: Alfa pharmaceutical company

Address before: Rome Italy

Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1148536

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170510

Termination date: 20210402